Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease - Haberman, Rebecca H; Herati, Ramin; Simon, David; Samanovic, Marie; Blank, Rebecca B; Tuen, Michael; Koralov, Sergei B; Atreya, Raja; Tascilar, Koray; Allen, Joseph R; Castillo, Rochelle; Cornelius, Amber R; et al. (Annals of the rheumatic diseases, 2021)
Keywords: Antibodies; arthritis; CD8 antigen; Cell activation; Coronaviruses; COVID-19; COVID-19 vaccines; Disease; Epidemiology; Flow cytometry; Immune response (cell-mediated); Immune response (humoral); Immunocompetence; Immunogenicity; Immunoglobulin G; Immunomodulation; Infections; Inflammatory diseases; Influenza; Lymphocytes T; Methotrexate; mRNA; mRNA vaccines; Patients; Proteins; Psoriasis; psoriatic; rheumatoid; Rheumatoid arthritis; Severe acute respiratory syndrome coronavirus 2; Software; Spike protein; Steroids; Tumor necrosis factor; Tumor necrosis factor-TNF; Tumors; vaccination; Vaccine efficacy; Vaccines; New York; United States--US; Germany; New York City New York; methotrexate; psoriatic; Covid-19; arthritis; rheumatoid; vaccination